雷公藤多苷联合RAS阻断剂治疗CKD 2~3期IgA肾病

发布时间：2018-02-09 13:50

本文关键词： 肾小球肾炎IA 雷公藤多苷慢性肾脏病 RAS阻断剂　出处：《实用医学杂志》2016年01期 　论文类型：期刊论文

【摘要】：目的:观察雷公藤多苷联合肾素-血管紧张素系统(RAS)阻断剂治疗慢性肾脏病(CKD)2~3期IgA肾病(IgAN)的疗效及安全性。方法:109例患者随机分为观察组(n=55)和对照组(n=54),在口服RAS阻断剂的基础上,观察组给予雷公藤多苷,对照组给予甲泼尼龙,观察两组尿蛋白与肾功能的变化及不良反应的发生率。结果:治疗后3、6、9、12个月,两组尿蛋白定量均显著低于基线值(P0.05)。随访期间,两组估算肾小球滤过率(eGFR)值与基线值相比差异无统计学意义(P0.05)。两组间尿蛋白、eGFR、总有效率比较差异无统计学意义。不良反应:观察组不良反应的发生率为9.8%,对照组为27.4%,比较差异有统计学意义(P0.05)。结论:雷公藤多苷联合RAS阻断剂能有效降低CKD 2~3期IgAN患者尿蛋白水平,保护肾功能,而且副作用较少,是CKD 2~3期IgAN有效的治疗模式之一。
[Abstract]:Objective: to observe the efficacy and safety of tripterygium wilfordii polyglycoside combined with renin-angiotensin system blocker (Ras) in the treatment of IgA nephropathy with chronic kidney disease (CKD2) stage 2.Methods: one hundred and nine patients were randomly divided into observation group (n = 55) and control group (n = 54). On the basis of blockers, The study group was given tripterygium wilfordii polyglycoside and the control group was given methylprednisolone. The changes of urinary protein and renal function and the incidence of adverse reactions were observed. There was no significant difference in the estimated glomerular filtration rate (GFR) between the two groups compared with the baseline value (P 0.05). There was no significant difference in the total effective rate between the two groups. Adverse reactions: the incidence of adverse reactions in the observation group was 9.8%, while that in the control group was 9.8%. Conclusion: Tripterygium wilfordii polyglycoside combined with RAS blocker can effectively reduce the level of urinary protein in patients with CKD 2 / 3 IgAN. Protection of renal function, and less side effects, is one of the effective treatment modes of CKD stage 2 and 3 IgAN.
【作者单位】：第三军医大学大坪医院野战外科研究所肾内科;
【基金】：国家十二五支撑计划项目(编号:2011BAI10B08)
【分类号】：R692.31

【相似文献】